People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Pharma, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Affinia Therapeutics Inc. | — | Pharma | Series D+ | $170.1M | $99.8M | 2025 |
| Adaptimmune Ltd | — | Biotechnology | Series D+ | $103.8M | $4.3B | 2014 |
Elliott Sigal at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elliott Sigal on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ali Behbahani | 1 | 17 |
| Peter Thompson | 1 | 16 |
| Edward Mathers | 1 | 12 |
| Robert Weisskoff | 1 | 12 |
| David Mott | 1 | 9 |
| Robert Johnson | 1 | 9 |
| David Grayzel | 1 | 6 |
| Rob May | 1 | 3 |
| Sean Nolan | 1 | 3 |
| Paula Cobb | 1 | 1 |
| Caroline Stout | 1 | 1 |
| Elliot Sigal | 1 | 1 |
| Charles Albright | 1 | 1 |
| Luk Vandenberghe | 1 | 1 |
| Dr. Jonathan Knowles | 1 | 1 |
| James Noble | 1 | 1 |
| Ian Laing | 1 | 1 |
| Carole Faig | 1 | 1 |
| Rami Daoud | 1 | 1 |
| Diana Brainard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.